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William H. Prusoff (1920–2011): Father of Antiviral
Chemotherapy
Yung-Chi Cheng*
Yale School of Medicine, New Haven, Connecticut, United States of America
Regarded as the father of antiviral
chemotherapy, William H. Prusoff (Bill)
passed away on April 3, 2011, in New
Haven, Connecticut. Dr. Prusoff spent
most of his career studying analogs of
thymidine, a nucleoside building block of
DNA, with an eye toward developing
therapeutic agents. By exploring analogs
to thymidine for use as antiviral drugs, his
research created a new scientific paradigm
for antiviral drug development.
In the late 1950s, Bill synthesized one of
the first thymadine analogs, 5-iododeoxy-
uridine. At the time, it was thought to be
difficult to find antiviral drugs with a high
therapeutic index, but Professor Herbert
E. Kaufman found that the compound
could be used as an effective topical
treatment for herpes virus keratitis by
disrupting the virus’s ability to reproduce.
More significantly, though, this discovery
was a scientific game changer—it was the
first time that a clinical antiviral drug had
been shown to have selective antiviral
activity if used properly.
My association with Bill started in the
early 1970s during my postdoctoral work
at Yale. Together with Professor David
Ward, we found that 59amino-5-iodode-
oxyuridine had a high degree of selectivity
against the herpes simplex virus in culture.
Around the same time, Dr. James Black
and Dr. Gertrude Elion at Burroughs
Wellcome found that acyclovir, another
nucleoside analog, also exhibited anti-
herpes virus behavior in culture. Scientif-
ically, these were major breakthroughs
because these two discoveries were the first
demonstrations of highly selective antiviral
drug behavior due to the unique proper-
ties of the herpes simplex virus. Subse-
quently, it was found that the selectivity
was due to the preferential activation of
compounds by viral specified thymidine
kinase. Due to an unexpected toxicity
found in young mice, 59amino-5-iodode-
oxyuridine was never further developed,
but acyclovirin went on to become the first
orally active anti-herpes virus drug.
In the 1980s, while the AIDS epidemic
was spreading and found to be caused by
HIV, Bill and the late Dr. Tai-Shun Lin
discovered that a compound synthesized
by Dr. Jerome Horwitz had potent anti-
HIV properties. The compound was
originally named D4T, and Bristol-Myers
Squibb developed and marketed this drug
under its more common name, Zerit. It
became a key drug as part of the first
combination therapy for treating AIDS.
Realizing that this treatment could pro-
vide great benefits to those struggling with
the growing HIV crisis in impoverished
Africa, Doctors Without Borders and Yale
students later lobbied Yale University and
Bristol-Myers Squibb to make Zerit avail-
able at a low cost for the African market.
Bill quickly joined the effort, even though
it meant a loss of personal income. ‘‘We
are not doing this to make money, we are
interested in developing a compound that
would be a benefit to society,’’ he
explained. The effort to make Zerit more
affordable was a success: millions of people
around the world benefited from Bill’s
research and humanitarian efforts.
Bill was born on June 25, 1920, in New
York City and attended the University of
Miami. After receiving his undergraduate
degree in chemistry, he obtained his PhD
from Columbia University and later com-
pleted his postdoctoral training in the
laboratory of Professor Arnold Welch at
Case Western Reserve University. After
Dr. Welch was recruited by Yale to head
the Medical School’s pharmacology de-
partment, Bill was invited to join the same
department as an assistant professor and
was subsequently promoted to the rank of
professor. This relationship at Yale would
span over the next 58 years, with Bill
becoming one of Yale’s most well respect-
ed scientists and teachers.
Though Bill officially retired at age 70,
he never stopped working and continued
to be industrious. Until his death, his work
as professor emeritus concentrated on the
potential for using boronated-thymidine
analogs as sensitizing cancer agents for
neutron therapy.
Bill’s remarkable contributions did not go
unnoticed in his lifetime. Among his many
accolades, he received the ASPET Award
from the American Society of Pharmacology
and Experimental Therapeutics and the
Peter Parker Medal, Yale School of Medi-
cine’s highest award. He also received the
Inaugural Lifetime Achievement Award
from the Yale Comprehensive Cancer
Center. His legacy was further solidified
when the School of Medicine established an
endowed chair in his name and the
Department of Pharmacology named one
of its conference rooms after him. In
addition, the International Society for Virus
Research established the William Prusoff
Young Investigator Lecture Award.
Despite his numerous awards and
prestigious accomplishments, Bill was an
extremely humble and down-to-earth man
who was quick to understate his achieve-
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with others. He lived modestly, unselfishly,
and with the highest integrity. These traits
made him an extremely popular and
highly respected individual everywhere. I
do not remember a time that anyone
would say anything bad about him. He
was always eager to assist others. As a
fellow at Pierson College here at Yale, he
would provide students with help but
never boasted or took credit. Bill also
generously contributed to charities, en-
dowing several lectureships in pharmacol-
ogy, virology, and public health at Yale,
supporting research in several laboratories,
and establishing the William H. Prusoff
Foundation to support various programs,
including the United Way and the Yale
Initiative for the Interdisciplinary Study of
Anti-Semitism. He dedicated his life to the
service of others because he saw generosity
and helping as a natural extension of the
human condition. He was a role model for
scholars to follow.
Bill was always upbeat, smiling and
ready with a joke. His lifelong optimism in
the worst of times was always inspiring—
he often said ‘‘the best is yet to come.’’
Even in the hospital under intense dis-
comfort, he kept a lighthearted and
positive disposition, making light of his
situation when we knew how serious it
was. He even kept on sending us jokes
through email when he couldn’t tell them
in person.
For those of us fortunate enough to
have personally known him, we were
gifted with his peculiar sense of humor,
warm welcoming company, and deep
wisdom. Bill’s influence was much broad-
er, though: training a new generation of
scientists who have gone on to become
successful in their own right, rippling with
their own contributions that have affected
others. For the millions of lives his work
has touched and saved, we have lost a
giant scientist in this age.
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